• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辛伐他汀单用与甜菜碱联合治疗高脂血症的对比及联合用药研究。

Comparative and combination study of simvastatin alone and in combination with Beta vulgaris in hyperlipidemia patients.

机构信息

Department Pharmacology, Baqai Medical University Karachi, Karachi, Pakistan.

Department Pharmacology Dow Medical College DUHS Karachi, Karachi, Pakistan.

出版信息

Pak J Pharm Sci. 2024 Sep;37(5):1033-1041.

PMID:39460970
Abstract

Phytomedicine is gaining acceptance as well preference in health care management for various diseases. Drug combinations are mostly used clinically for hyperlipidemia, as single-agent therapy is insufficient. Statins remain the cornerstone of hyperlipidemia. The objective of the present research is to manage hyperlipidemia with the least amount of medicine effective clinically, thereby limiting its side effects. Study was carried out with 140 registered hyperlipidemia patients, divided into two groups. Group-A received simvastatin 20mg oral daily & Group B received a combination of simvastatin and beta-valgaris capsules twice a day for 90 days. Pre and post treatment values were compared within the groups and between the groups. Group B shows statistically significant decrease (p<0.05) in serum total cholesterol, low density lipoprotein (LDL), triglycerides (TG) and CRP levels. Also significant improvement (p<0.05) was noted for high density lipoprotein (HDL) levels (20.1% to 57.4%) in group B after completion of study. On the basis of our study results, we can conclude that statins remained to be the mainstay treatment for patients with elevated cholesterol levels. However, the combination has a synergistic effect and reduces oxidative stress (OS) as well.

摘要

植物药在各种疾病的医疗保健管理中越来越受到认可和青睐。药物联合治疗在临床上主要用于治疗高血脂症,因为单一药物治疗效果不足。他汀类药物仍然是高血脂症的基石。本研究的目的是以最少量有效的药物来管理高血脂症,从而限制其副作用。研究共纳入 140 名注册高血脂症患者,分为两组。A 组给予辛伐他汀 20mg 口服,每日一次;B 组给予辛伐他汀和β-缬草胶囊联合治疗,每日两次,疗程为 90 天。在组内和组间比较治疗前后的数值。B 组的血清总胆固醇、低密度脂蛋白(LDL)、甘油三酯(TG)和 C 反应蛋白(CRP)水平均有统计学意义的降低(p<0.05)。研究结束后,B 组的高密度脂蛋白(HDL)水平也有显著改善(p<0.05)(从 20.1%提高到 57.4%)。基于我们的研究结果,我们可以得出结论,他汀类药物仍然是治疗胆固醇水平升高患者的主要治疗方法。然而,联合治疗具有协同作用,并且还可以降低氧化应激(OS)。

相似文献

1
Comparative and combination study of simvastatin alone and in combination with Beta vulgaris in hyperlipidemia patients.辛伐他汀单用与甜菜碱联合治疗高脂血症的对比及联合用药研究。
Pak J Pharm Sci. 2024 Sep;37(5):1033-1041.
2
Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.混合性高脂血症患者联合使用他汀类药物与贝特类药物治疗与单一药物治疗的比较。
Kardiol Pol. 2004 Jun;60(6):567-77.
3
Effect of Taizhi'an capsule combined with Simvastatin on hyperlipidemia in diabetic patients.泰脂安胶囊联合辛伐他汀对糖尿病患者高脂血症的影响
Chin J Integr Med. 2006 Mar;12(1):24-8. doi: 10.1007/BF02857425.
4
Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.单纯使用小檗碱或联合他汀类药物治疗高脂血症的疗效和安全性:一项随机对照临床试验的系统评价和荟萃分析。
Am J Chin Med. 2019;47(4):751-767. doi: 10.1142/S0192415X19500393. Epub 2019 May 16.
5
[Efficacy and tolerability of statins in patients with primary hyperlipidemias].他汀类药物在原发性高脂血症患者中的疗效及耐受性
Kardiologiia. 2005;45(9):32-4.
6
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.辛伐他汀对混合性高脂血症和高甘油三酯血症患者C反应蛋白的影响。
Am J Cardiol. 2002 Nov 1;90(9):942-6. doi: 10.1016/s0002-9149(02)02658-9.
7
[Effect of xuezhikang on the treatment of primary hyperlipidemia].血脂康对原发性高脂血症的治疗作用
Zhonghua Nei Ke Za Zhi. 1997 Aug;36(8):529-31.
8
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.在高脂血症患者中,依折麦布/辛伐他汀与烟酸缓释剂联合应用对脂蛋白颗粒数的影响。
J Am Heart Assoc. 2013 Aug 7;2(4):e000037. doi: 10.1161/JAHA.113.000037.
9
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.非诺贝特(200毫克/天)联合辛伐他汀(10毫克/天)对混合性高脂血症合并代谢综合征患者的影响。
Am J Cardiol. 2003 Apr 15;91(8):956-60. doi: 10.1016/s0002-9149(03)00111-5.
10
Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.辛伐他汀和高脂血症与牙周状况及骨代谢标志物的关联。
J Periodontol. 2014 Oct;85(10):1408-15. doi: 10.1902/jop.2014.130652. Epub 2014 Feb 21.

引用本文的文献

1
Formation of PEG-PLGA Microspheres for Controlled Release of Simvastatin and Carvacrol: Enhanced Lipid-Lowering Efficacy and Improved Patient Compliance in Hyperlipidemia Therapy.用于辛伐他汀和香芹酚控释的聚乙二醇-聚乳酸-羟基乙酸共聚物微球的制备:在高脂血症治疗中增强降脂疗效并改善患者依从性
Polymers (Basel). 2025 Feb 21;17(5):574. doi: 10.3390/polym17050574.